Thinking about buying stock in Jounce Therapeutics, Kala Pharmaceuticals, Nano-X Imaging, F-Star Therapeutics, or Pagaya Technologies? Thinking about buying stock in Jounce Therapeutics, Kala Pharmaceuticals, Nano-X Imaging, F-Star Therapeutics, or Pagaya Technologies? PR Newswire NEW YORK, Dec...

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment including a PD-1 inhibitor showed a durable partial response with ...

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in improved mean tumor change over 9 and 18 weeks, and secondary endpoints of overall response rate (ORR...

Woodline Partners LP acquired a new stake in Jounce Therapeutics, Inc. (NASDAQ:JNCE Get Rating) in the fourth quarter, Holdings Channel reports. The firm acquired 1,359,528 shares of the companys stock, valued at approximately $11,352,000. Several other hedge funds have also made ...